These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 37481927)

  • 1. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
    Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
    Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.
    Luo Y; Li C; Zhang Y; Liu P; Chen H; Zhao Z; Wang Y; Zhou Z; Song H; Su B; Li C; Li X; Zhang T; You H; Wu Y; Tian Z; Zhang S; Guo Y; Fan H; Chen Q; Jiang C; Sun T
    Acta Biomater; 2023 Sep; 167():387-400. PubMed ID: 37276955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.
    Poyia F; Neophytou CM; Christodoulou MI; Papageorgis P
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the metabolism and immune system in pancreatic ductal adenocarcinoma: Insights and future directions.
    Bandi DSR; Sarvesh S; Farran B; Nagaraju GP; El-Rayes BF
    Cytokine Growth Factor Rev; 2023; 71-72():26-39. PubMed ID: 37407355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer.
    Lu T; Prakash J
    Int J Nanomedicine; 2021; 16():6313-6328. PubMed ID: 34552327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
    Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
    Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
    [No Abstract]   [Full Text] [Related]  

  • 10. A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer.
    Tong QS; Miao WM; Huang H; Luo JQ; Liu R; Huang YC; Zhao DK; Shen S; Du JZ; Wang J
    Small; 2021 Jul; 17(29):e2101208. PubMed ID: 34145747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of pancreatic cancer therapy resistance by chemokines.
    Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon?
    Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B
    Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
    Song H; Jiang C
    Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer.
    Guo J; Wang S; Gao Q
    Front Immunol; 2023; 14():1258538. PubMed ID: 37771596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal Homeostasis-Restoring Nanomedicine Enhances Pancreatic Cancer Chemotherapy.
    Yu N; Zhang X; Zhong H; Mu J; Li X; Liu T; Shi X; Liang XJ; Guo S
    Nano Lett; 2022 Nov; 22(21):8744-8754. PubMed ID: 36279310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
    Yu S; Zhang C; Xie KP
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
    Wang Z; Wu B; Nie G; Wei J; Li Y
    Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
    Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
    Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.